Heartflow (NASDAQ:HTFL) Stock Rating Lowered by Wall Street Zen

Heartflow (NASDAQ:HTFL) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

HTFL has been the topic of several other reports. JPMorgan Chase & Co. lifted their price objective on shares of Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. Stifel Nicolaus boosted their target price on shares of Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Benchmark restated a “buy” rating on shares of Heartflow in a report on Friday, August 14th. UBS Group initiated coverage on Heartflow in a report on Wednesday, September 9th. They issued a “neutral” rating and a $55.00 target price for the company. Finally, Freedom Capital raised Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Heartflow currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.25.

Heartflow Price Performance

Heartflow stock opened at $48.29 on Friday. The firm’s 50 day simple moving average is $47.26 and its 200-day simple moving average is $35.34. The company has a market cap of $4.20 billion, a P/E ratio of -26.39 and a beta of 2.73. Heartflow has a fifty-two week low of $20.13 and a fifty-two week high of $54.32.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. The business had revenue of $64.08 million for the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. On average, analysts expect that Heartflow will post -0.75 EPS for the current fiscal year.

Insider Transactions at Heartflow

In related news, CFO Vikram Verghese sold 16,766 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $50.75, for a total transaction of $850,874.50. Following the transaction, the chief financial officer directly owned 155,183 shares of the company’s stock, valued at approximately $7,875,537.25. The trade was a 9.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 19,682 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $50.15, for a total transaction of $987,052.30. Following the transaction, the insider directly owned 79,956 shares in the company, valued at $4,009,793.40. The trade was a 19.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 304,105 shares of company stock valued at $14,173,800 over the last three months. 7.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Heartflow

A number of institutional investors have recently modified their holdings of HTFL. XXEC Inc. acquired a new position in shares of Heartflow in the second quarter worth $2,524,764,000. BlackRock Inc. purchased a new stake in shares of Heartflow during the second quarter worth $152,502,000. Bamco Inc. NY acquired a new stake in Heartflow during the second quarter valued at $94,625,000. Jupiter Topco LLC acquired a new stake in Heartflow during the second quarter valued at $70,983,000. Finally, Janus Henderson Group PLC boosted its position in Heartflow by 152.0% during the first quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock valued at $53,063,000 after purchasing an additional 1,315,416 shares during the last quarter.

Heartflow Company Profile

HeartFlow, Inc is a medical technology company focused on improving the diagnosis and management of coronary artery disease. The company develops software and clinical tools that use artificial intelligence, advanced image analysis and data from coronary computed tomography angiography (CCTA) scans to provide noninvasive assessments of blood flow and potential blockages in the heart.

Its principal product is the HeartFlow Analysis, which creates a personalized, three-dimensional model of a patient’s coronary arteries and can estimate the impact of blockages on blood flow.